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Abstract

Background and aims Pharmaceutical opioid prescription rates are increasing globally, however knowledge
of their long-term effects on mental health, in particular depression remains limited. This study aimed to
identify factors associated with the onset of depression post-opioid use that differ to factors associated with
depression post-pain. Method Participants (N=1 418) were a national sample prescribed opioids for chronic
non-cancer pain. Age at onset of depression, pain and commencement of opioid medications were collected
via structured interview. Results Six in 10 (61%) reported lifetime depression; of those, almost half developed
depression after pain and after they started opioid medications (48%). Variables associated with post-opioid
depression included lower pain self-efficacy and poorer social support, younger onset of opioid use, and
difficulties and concerns with opioid medications. Conclusions The findings highlight the importance of
monitoring for the emergence of mood dysfunction, particularly for those starting opioids for pain at a
younger age, and consideration of psychological treatments that address self-efficacy that appears to be
associated with post-opioid depression.
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Abstract
Background and aims: Pharmaceutical opioid prescription rates are increasing globally,
however knowledge of their long‐term effects on mental health, in particular depression
remains limited. This study aimed to identify factors associated with the onset of depression
post‐opioid use that differ to factors associated with depression post‐pain.
Method: Participants (N=1,418) were a national sample prescribed opioids for chronic non‐
cancer pain. Age at onset of depression, pain and commencement of opioid medications
were collected via structured interview.
Results: Six in ten (61%) reported lifetime depression; of those, almost half developed
depression after pain and after they started opioid medications (48%). Variables associated
with post‐opioid depression included lower pain self‐efficacy and poorer social support,
younger onset of opioid use, and difficulties and concerns with opioid medications.
Conclusions: The findings highlight the importance of monitoring for the emergence of
mood dysfunction, particularly for those starting opioids for pain at a younger age, and
consideration of psychological treatments that address self‐efficacy that appears to be
associated with post‐opioid depression.
Keywords: depression, chronic pain, pharmaceutical opioids, self‐efficacy

Introduction
The global prevalence of chronic non‐cancer pain (CNCP) is estimated at one adult in five,
(1) with the 2010 Global Burden of Disease Study reporting chronic low back pain as the
largest cause of years lost to disability (2).
Pharmaceutical opioids are increasingly used for treatment of CNCP. (3). Despite the link
between CNCP and poorer mental health being well established in the literature (4, 5), little
is known about the impact thatcommencement of prescribed opioids may have on this
relationship (i.e., is use of opioids associated with an increased or decreased likelihood of
depression).
A growing body of research has focused on “adverse selection” (6) whereby individuals with
pre‐existing mental illness are more likely to be prescribed pharmaceutical opioids for CNCP
and at higher doses (7). A recent cohort study found individuals who were receiving opioid
treatment were more likely to report high levels of psychological distress compared with
individuals not receiving opioid medications (8). Additionally, opioid‐naïve patients with
chronic pain without a recent history of depression have been found to be at greater risk of
developing depression the longer they were taking opioid medications (9).
With an ageing population in Western countries and increasing opioid prescribing in many
of these, it is timely to assess the possible association between pharmaceutical opioids and
risk of developing depression. The current study examines data from a large community
sample, including in‐depth measures of mental health, and self‐reported opioid
consumption (rather than prescribing data), while controlling for severity of pain and pre‐
existing depression.
The aims of the study were:
(a) to estimate the prevalence of depression that occurs after the onset of pain and also
after the initiation of prescribed opioid treatment for pain;
(b) to determine demographic and clinical characteristics and factors associated with those
who develop depression post‐pain; and
(c) to determine demographic and clinical characteristics and factors associated with those
who develop depression post‐opioid treatment.

Methods
Study Design
This study draws on baseline data collected for the Pain and Opioids IN Treatment (POINT)
study, a national cohort of 1,514 individuals taking pharmaceutical opioids for chronic non‐
cancer pain. Recruitment of this cohort has been described elsewhere (10). In brief,
community pharmacists referred patients prescribed strong opioids to complete a
telephone interview and self‐complete survey at baseline and then three further time
points.
The study was approved by the Human Research Ethics Committee of the University of New
South Wales, Australia (HREC reference: #HC12149). It also received A1 Australian National
Pharmacy Guild Approval to approach pharmacists to assist with recruitment (Approval
#815).
Eligibility Criteria
POINT participants were screened and considered eligible if they were 18 years or older;
competent in English; mentally and physically able to complete telephone and self‐complete
interviews; living with chronic non‐cancer pain for at least 3 months; prescribed a restricted
opioid (such as morphine, oxycodone, fentanyl or codeine as a single ingredient which are
classified under schedule 8 in the Australian Uniform Scheduling of Medicines and Poisons,
Poisons Standard 2012 (11)); meaning they are controlled drugs subject to restrictions to
reduce abuse, misuse and dependence) and having taken such opioids for CNCP for more
than 6 weeks. A history of injecting drug use (IDU) did not exclude participation, however
those currently prescribed pharmaceutical opioids solely as opioid substitution therapy
(OST) for heroin dependence, or those being treated with opioids for cancer pain, were not
eligible.
Participants
For the purpose of the current study, only participants who contributed data on the age at
onset of depression, age at onset of pain and age at commencing pharmaceutical opioids
were included in the analyses (n=1,418). Those who reported lifetime depression (n=860)

for descriptive purposes could be divided into three groups; those who developed
depression prior to pain (n=236); those who developed depression after the onset of pain
but prior to commencing opioids (n=205 excluding missing data); and those who developed
depression after pain and after they started opioid medications (n=416).
To compare the temporal relationships between onset of pain and onset of depression,
participants who reported whether or not they had experienced lifetime depression
(n=1,379) were divided into three groups: the ‘no depression’ group included those who
reported no lifetime history of depression (n=519); those whose age at onset of depression
preceded their age at onset of pain reported were assigned to the ‘pre‐pain depression’
group (n=236); and those whose age at onset of pain preceded their age at onset of
depression were assigned to the ‘post‐pain depression’ group (n=624). Due to missing data
on the essential age at onset variables, 39 cases were not included.
To compare the temporal relationships between onset of opioid treatment and onset of
depression, n=1,361 participants were allocated to three groups according to whether the
onset of depression occurred before or after the initiation of opioid treatment. As above,
the ‘no depression’ group reported no lifetime history of depression (n=519); those who
reported that depression preceded commencement of opioid medications were assigned to
the ‘pre‐opioid depression’ group (n=426); and those whose commencement of opioids
preceded depression were assigned to the ‘post‐opioid depression’ group (n=416). Due to
missing data on the essential age at onset variables 57 cases were not included.
Measures
The measures, tools, and domains collected were based on recommendations made under
the auspices of the Initiative on Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) (12, 13). Full details of the measures used in the study have been
documented elsewhere (10), and are described briefly below.
Pain and physical health related measures
Data were collected on participants’ pain history. The Brief Pain Inventory (14) was utilised
to assess current pain severity and interference from pain on a rating scale from 0 to 10,
with higher scores indicative of higher pain severity and interference. Pain‐related self‐

efficacy beliefs were assessed using the Pain Self‐Efficacy Questionnaire (PSEQ) (15) which
generates a total score from 0‐60. Higher scores on the scale reflect greater confidence in
the participant’s ability to perform a range of activities including household chores,
socialising, work and to cope with pain. The Washington Group Scale (16) was used to
measure physical functioning providing a total score between 0‐18, with higher scores
indicating greater degrees of disability.
Mental health and substance use
Participants were asked if they had ever been diagnosed with any mental health condition,
including depression, anxiety, post‐traumatic stress disorder, and borderline personality
disorder. Current depression and anxiety were assessed through scores on the PHQ‐9 (17)
and GAD‐7 (18) from the Patient Health Questionnaire (19). Continuous scores on the Social
Interaction Anxiety Scale (SIAS‐6) (20) and Social Phobia Scale (SPS‐6) (20) were used to
derive current symptoms of social anxiety and phobia. Current agoraphobia and panic
disorder were screened using the Mini International Neuropsychiatric Interview (MINI) (21),
each coded as binary variables. Using the National Survey of Mental Health and Wellbeing
(22) version of the Composite International Diagnostic Interview (CIDI) participants were
screened for possible diagnoses of borderline personality disorder in accordance with
International Classification of Diseases‐10 (ICD‐10) criteria. Post‐traumatic stress disorder
(PTSD) was measured using the Primary Care PTSD screen (PC‐PTSD) with three or more
symptoms in the past month indicative of current PTSD (23).
Participants were asked about lifetime and past 12 month alcohol and illicit drug use apart
from pharmaceutical opioids, as difficulties with opioids were measured using PODS.
Lifetime drug and alcohol use disorders were assessed via the CIDI (24) alcohol and illicit
drug use module in accordance with ICD‐10 criteria. Any lifetime substance use disorder
included both harmful use and dependence with current symptoms defined as more than 3
experienced in the past 12 months.
Opioid medications
Participants were asked about opioid medication history. Daily oral morphine equivalent
(OME) doses (mg) were calculated using published conversion rates that were synthesised
from international literature (25). OME was calculated for each participant from the 7‐day

medication diary which took into account all type of opioids, including over‐the‐counter,
that the participant self‐reported they had taken in the preceding week. A weekly mean was
calculated, taking to account any changes in OME over the week, and OME daily dose was
derived from that.
To assess participants’ current concerns and problems in regards to the use of prescription
opioids the Prescribed Opioids Difficulty Scale (PODS) (26) was included. The 15‐item scale
generates a continuous score out of 60; a cut‐off of ≥8 indicates at least intermediate levels
of participant concern or difficulties (26).
Data Analysis
All analyses were conducted using IBM SPSS statistics v22 (SPSS, INC., Chicago. IL, USA). The
groups established on the basis of onset of depression were compared with respect to
demographic factors, current pain and pain history, opioid medications and current and
lifetime mental health and substance use. Analyses applied logistic regression models with
odds‐ratios and 95% confidence intervals for categorical variables; means and t‐tests for
normally distributed continuous variables; and medians, inter‐quartile range, and Mann‐
Whitney U for non‐normal continuous variables.
Univariate and multivariate multinomial regression models were conducted to examine
factors associated with a) depression following the onset of pain; and b) depression
following the onset of treatment with opioids. Relative Risk ratios (RRR) and 95%CI are
reported. In this series of analyses, for consistency between univariate and multivariate
models, only participants who had completed the baseline interview, survey and medication
diary were included. All variables were entered into multivariate models and were
controlled for in addition to mental health problems:, PTSD, agoraphobia, panic and
borderline personality. When examining factors associated with developing depression after
the onset of pain, complete data from n=809 participants were included. A multivariate
logistic regression was also performed to examine any characteristic differences between
those who developed depression after pain but before opioids (n=205) and those who
developed depression after pain and after opioids (n=416).

Results
Demographic, pain and medication characteristics
Of the 1418 participants in this analysis, 44% were male with a median age of 58 years
(IQR=48‐68). The average pain duration was 10 years (IQR=4.5‐20) with current pain severity
rated at a mean of 5.1 (SD=1.8), and mean pain interference of 5.7 (SD=2.3) Participants
reported taking pharmaceutical opioids continuously for a median of 4 years (IQR=1.5‐10)
with the average daily oral morphine equivalent dose being 70mg (IQR=35mg‐142mg). Sixty‐
one percent of participants reported a lifetime incidence of depression.
When comparing the 39 missing cases not included in the analyses according to onset of
depression post‐pain, there were no significant differences in gender, age, pain duration,
pain severity or OME dose. However, those omitted from the analyses reported a longer
duration of opioid use (Mdn=10, IQR=4‐13). There were no significant differences between
the 57 missing cases and those included in the analyses according to onset of depression
post‐opioids in gender, age, pain duration, opioid treatment duration or OME dose.
However, those excluded from the analyses reported a greater pain severity (M=5.8,
SD=1.7).
Group comparisons according to onset of depression post‐pain.
. Overall, measures of pain and medication use distinguished participants with a lifetime
history of depression from their counterparts without depression, regardless of time of
onset. Compared with the ‘pre‐pain depression’ group, the ‘post‐pain depression’ group was
more likely to be male and have a lower income (Table 1). Compared with both the ‘no‐
depression’ group and ‘pre‐pain depression’ group, the ‘post‐pain depression’ group was
more likely to have changed employment status due to pain, tended to have been
experiencing pain for longer, reported greater pain interference, poorer physical functioning
as observed through higher scores on the Washington Group Scale and reported a higher
number of medication side effects. They had started taking pharmaceutical opioids at a
younger age and had used them for longer. Compared with the ‘no‐depression’ group, the
‘post‐pain depression’ group was younger, less likely to be in a relationship, reported
greater pain severity and less confidence in ability to cope with pain (as measured with the

PSEQ). The ‘post‐pain depression’ group reported a higher OME dose and was more likely to
have problems or concerns about their opioid medications than the ‘no‐depression’ group.
The ‘post‐pain depression’ group was more likely to report lower social support, any of the
mental health conditions examined, or a lifetime history of substance use disorders
compared with those reporting no depression.
INSERT TABLE 1.
Associations with developing depression post‐pain.
From the multivariate analysis, factors associated with developing depression before onset
of pain, compared with those who had never developed depression were; a younger age,
female, not being in a current relationship, a lower pain self‐efficacy score, older at onset of
pain, reported more problems associated with their opioid medication but reported fewer
side effects from medication. Factors associated with developing depression post‐pain
(compared with those who never developed depression) were being female, a change in
employment status due to pain, poorer pain self‐efficacy, poorer physical functioning, a
younger age of onset of pain and lower levels of social support (Table 2).
INSERT TABLE 2.
Group comparisons according to onset of depression post‐opioids.
The ’post‐opioid depression’ group was more likely to be male than the ‘pre‐opioid
depression’ group (Table 3). Compared with the ‘no depression’ group, the ‘post‐opioid
depression’ group was less likely to be in a relationship, reported greater pain severity and
interference, less confidence in coping with pain (as measured with the PSEQ), reported
poorer physical functioning and was more likely to report all mental health conditions
and/or a lifetime substance use disorder. Compared with both the ‘no‐depression’ group
and ‘pre‐opioid depression’ group, the ‘post‐opioid depression’ group was significantly
younger, and more likely to have changed employment status due to pain. The ‘post‐opioid
depression’ group reported higher OME doses, had started pharmaceutical opioids at a
younger age and had taken them for longer. They were more likely to have an intermediate
to high score on the PODS (indicating greater difficulties with their pharmaceutical opioids)
than the other two groups, reported a higher number of medication side effects and had

higher scores on measures of current social anxiety and social phobia than either of the
other groups.
INSERT TABLE 3.
Associations with developing depression post‐opioids
From the multivariate analysis, participants that developed depression pre‐opioids,
compared with those that never developed depression were, younger, female, less likely to
be in a relationship, lower pain and self‐efficacy score, poorer physical health, younger at
age of pain onset and older at opioid medication initiation. Participants who developed
depression following opioid use were identified as having started pharmaceutical opioids at
a younger age, poorer physical health, more likely to report difficulties with their opioid
medications and having less social support. (Table 4).
Comparison of those who developed depression post‐pain, pre‐opioid with those who
developed depression post‐pain, post opioid
A multivariate analysis was conducted to compare those who developed depression after
the onset of pain but before commencement of opioid (n=205) with those who developed
depression after commencement of opioids (n=416), using the same variables as listed in
Tables 2 and 4 (not shown). Developing depression post‐opioids was associated with
increased odds of being older 1.05 (95% CI, 1.01‐1.08) , being male (OR= 1.75; 95% CI, 1.00‐
3.07), being older at age of pain onset (AOR= 1.09; 95% CI, 1.06‐1.11) and being younger at
commencement of pharmaceutical opioids (AOR = 0.88; 95% CI, 0.85‐0.91). All other
variables did not significantly differ.
INSERT TABLE 4.

Discussion
Although the association between chronic pain and depression has been documented (4, 5),
less work has examined the potential impact of pharmaceutical opioid therapy on the timing
of development of depression. The current study aimed to identify factors associated with
depression developing after the commencement of opioid medications that might differ
from those associated with the onset of pain itself. Where previous research has been
limited by measuring opioid use through prescriptions or specific populations (8, 9), the
current study is unique in using a community sample self‐reporting consumption of opioids,
including those purchased over the counter, and additionally controlling for pain‐related
factors.
Prevalence and characteristics of depression in a chronic pain sample
Consistent with other literature in the area (5) the prevalence of depression in this cohort
was high, with more than 60% of the sample experiencing depression at some point in their
lifetime, 66% of those reporting symptoms in the past 12 months, and 46% reporting
symptoms of moderate to severe depression in the past two weeks. Of those 60% (n=860)
who reported lifetime depression, around a quarter developed depression prior to pain
(n=236), a quarter (n=205 excluding missing data) developed depression after the onset of
pain but prior to commencing opioids, whilst almost half developed depression after pain
and after they started opioid medications (n=416). Compared with those with no history of
depression, those who reported depression also reported a greater number of medication
side effects, greater pain severity and interference, more opioid medication‐related
problems, and were more likely to report current mental health and substance use
problems, irrespective of whether their depression developed following the onset of pain or
of commencing opioids for pain. Thus, these results indicate a complex group experiencing a
multitude of difficulties and possibly requiring a multidisciplinary healthcare approach to
address their needs.
Furthermore, all depression groups reported taking a higher daily oral morphine equivalent
dose than the non‐depressed groups, lending support to the concept from research of
adverse selection (6, 7), and raising the important questions of how best to concurrently
treat pain and mental health and how to manage risk of adverse effects associated with

higher doses of opioids in this group. Long‐term follow up studies of patients naïve to opioid
medications would be better able to address this issue.
Factors associated with developing depression after the onset of pain
Factors associated with developing depression post‐onset of pain, after controlling for all
other variables in the multivariate analyses, included having poorer physical functioning,
lower levels of pain self‐efficacy, being younger at the onset of pain and having lower social
support. This highlights the need to pay particular attention to the mental health of those
presenting with pain at a young age. Social support and appreciation of self‐efficacy in
relation to pain may be modifiable factors that could respond to psychological therapies
such as CBT, self‐help or support groups (27, 28). Multimodal pain treatments (including
psychological therapies) have been shown to be effective in treating chronic pain (29, 30).
The context of this sample coming from a pain cohort must also be kept in mind. The bi‐
directional relationship between pain and depression may affect treatment options
considered by physicians, noting findings that depression may change the experience of
pain. “Major therapeutic implications arise out of this relationship (12, 31).”
Factors associated with developing depression after commencing opioid medications
In the current study, those who

no history of depression prior to starting opioid

medications, who went on to develop depression were more likely to have commenced
opioid medication at a younger age, to have experienced greater difficulties with their
opioid medications and to have less social support. Those who developed depression after
opioids (and after pain) differed from those who developed depression prior to commencing
opioids (but after pain) tending to be older, more likely to be male, were older at age of pain
onset and younger at age of starting opioid medications. Whereas previous findings (7, 9)
suggested that dose and duration of opioid medication were related to depression, these
variables were not found to be significant once controlling for important factors such as
duration of pain and concurrent mental health conditions.
There are a number of possible explanations for the relationship between opioid treatment
for pain and development of depression. Scherrer et al. (2013) applied neural research on
addiction (32) to suggest that opioids may increase the threshold of the ‘reward pathway’ so

that previous instigators of pleasure are no longer able to induce the same effect.
Alternatively, there is the possibility that sedative effects of opioid medications may induce
symptoms associated with depression (33). A further possibility is ‘substance‐induced
depressive disorder’ as stated in DSM 5 (34). This would be particularly problematic in those
who may be using medications, alcohol or other substances as a method of coping,
emphasising the need for non‐medication therapies for pain to be thoroughly explored.
Most likely, a number of psychosocial factors are involved with the development of
depression. For instance poorer coping, multiple health conditions and chronic illness have
been shown to affect mood (35) in addition to lower social support and change in lifestyle,
such as being unable to work.
Interestingly, those who developed depression prior to the commencement of opioids
tended to commence opioids at an older age compared with the no depression group. This
is in contrast to those who developed depression post‐opioids who tended to commence
opioids at a younger age than the no depression group. Similarly, those who developed
depression prior to the onset of pain tended to be older at the onset of pain compared to
the no depression group, whereas those who developed depression post‐pain tended to be
younger at the onset of pain. This may indicate that physicians were reluctant to prescribe
opioid medications to people already experiencing depression, contrary to previous
research on adverse selection (6, 7). Alternatively, it may be that people experiencing
depression delayed seeking help for their chronic pain and consequently, delayed
treatment.
The relationship between starting pharmaceutical opioids at a younger age and developing
depression may reflect other stressors, such as dealing with high levels of pain, side effects
from opioid medications and disability (when being younger is usually associated with being
in good health), as seen through the increased likelihood of changed employment status.
However neither current physical functioning nor pain severity was observed to be
significantly related to post‐opioid depression, and interestingly the relationship remained
significant when controlling for age at pain onset. An alternate explanation may consider
the role of the prescriber, whereby the physician is responding to a high level of distress,
particularly in a younger patient, by prescribing opioid medications for “pain” rather than
exploring other factors that may be contributing. This raises the issue of whether prescribing

opioids in such circumstances is appropriate and reinforces the need for a thorough
assessment of psychosocial background prior to initiating opioid treatments.
The more complex profile of health needs in the younger participants of this chronic pain
sample has been examined in more detail elsewhere (36). However, in light of an increased
likelihood of younger participants reporting problems and concerns about their opioids
(PODS), it is possible that this group may be trying to self‐manage depression or other
distress through their opioid medications or

other substances: this has been termed

‘chemical coping’ (37). Although not possible to confirm with our study design, future work
may be able to explore this hypothesis.
Limitations and implications
Due to the design of the study, data on onset of depression, pain and opioid
commencement were collected retrospectively and hence are dependent on participant
recall. Future research may investigate this temporal relationship prospectively, through
following patients who are naïve to opioid medications and by undertaking regular
assessments of emotional wellbeing, including the impact of effective treatments for mood
disorders on pain outcomes. Further, there is the possibility that participants’ self‐report of
depression may not be concordant with a clinical diagnosis of depression. Due to the nature
of the POINT study, this concordance could not be measured. It is important to note that
this study has addressed characteristics of the participant taking prescription opioids but the
role of the prescribers of such medicines was not explored (38).
Although it is not possible to interpret the relationship between depression and opioid
medications in terms of causality, specifically, whether difficulties and concerns surrounding
opioid use may contribute to depression or vice versa, the findings still have important
implications. All depression groups were experiencing a wide range of difficulties,
highlighting the need to screen for, and appropriately respond to, risk‐factors in opioid
prescribing (39) and closely monitor for evidence of beneficial effect from opioids and
emergence of problematic behaviours (40). Furthermore, in accordance with clinical
guidelines, it is important for physicians to recognise the importance of screening for
depression prior to initiating treatment for pain and to monitor for the emergence of mood
dysfunction during the course of treatment, especially in individuals with the risk

characteristics that have been raised here. Psychological interventions may be of benefit for
depression symptoms given evidence of their effectiveness in both depression and pain, and
additionally provide a possible intervention without increasing medication use, and hence
risk of sedative effects (41).
Conclusions
Although there are similarities between those who develop depression following the onset
of pain and those who develop depression after initiating opioid treatment for pain, the
latter group, especially those commencing opioids at a younger age appear to be a greater
risk of poorer outcome of treatment for pain and of developing difficulties with their opioid
medications. These results reflect the complex comorbidities of chronic pain, especially
depression and underscore the necessity for multidimensional assessment.
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Table 1. Demographic characteristics, mental health, pain and opioid medication history of POINT sample with and without depression broken down by onset of pain.
A. No depression (N=519)
Demographics
Age (years) Mdn (IQR)
64 (53‐72)
Male (%)
48.9
Income <$400 (%)
57.6
Completed tertiary education (%)
34.5
Changed employment status (%)
50.3
In a relationship (%)
63.6
Current Pain and Pain History
Pain duration (years) Mdn (IQR)
10 (4‐20)
Age at onset of pain (years) Mdn (IQR)
35 (23‐50)
Pain severity (BPI) M(SD)
4.8 (1.9)
Pain interference (BPI) M(SD)
4.9 (2.2)
Pain self‐efficacy (PSEQ) M(SD)
34.4 (13.2)
Physical functioning (Washington Group Scale) M(SD)
3.5 (2.0)
Opioid Medication
Opioid dose (OME) Mdn (IQR)
58.6 (25‐102.9)
Age at onset of opioid medication (years) Mdn(IQR)
49.0 (35.0‐64.0)
Duration of opioids (years) Mdn (IQR)
4 (1.5‐9)
Pharmaceutical opioid difficulties (PODS) (% endorsed
50.5
intermediate to high problems)
Medication side effects M(SD)
2.7 (2.2)
Current Mental Health
Social Support (MOS‐SS) M(SD)
3.5 (1.1)
Depression (PHQ score) M(SD)
6.2 (5.4)
General anxiety (GAD score) M(SD)
3.0 (3.9)
Social anxiety (SIAS‐6) Mdn (IQR)
0 (0‐1)
Social phobia (SPS‐6) Mdn (IQR)
0 (0‐1)
PTSD (PC‐PTSD)(%)
6.6
Agoraphobia (MINI) (%)
8.1
Panic (MINI) (%)
5.6
Borderline personality disorder (CIDI) (%)
2.9
Substance Use
Any lifetime substance use disorder1 (%)
27.2
Notes: 1. Excluding pharmaceutical opioids; *=p≤.05, **=p≤.01, ***=p≤.001.

B. Pre‐pain depression
(N=236)

C. Post‐pain depression
(N=624)

C vs A (ref)

C vs B (ref)

55 (44‐65)
33.5
53.0
37.7
60.6
50.4

55 (47‐64)
43.6
60.8
34.5
73.8
55.4

0.96 (0.95‐0.97)***
0.81 (0.64‐1.02)
1.14 (0.90‐1.45)
1.00 (0.78‐1.28)
2.79 (2.18‐3.58)***
0.71 (0.56‐0.91)**

1.01 (0.99‐1.02)
1.54 (1.12‐2.10)**
1.38 (1.02‐1.87)*
0.87 (0.64‐1.19)
1.84 (1.34‐2.52)***
1.22 (0.91‐1.65)

8 (3‐17)
40 (26‐50)
5.0 (1.8)
5.7 (2.4)
26.9 (12.3)
4.3 (2.1)

12 (5‐23)
22 (15‐35)
5.3 (1.7)
6.2 (2.1)
26.2 (13.1)
4.7 (2.3)

1.01 (1.00‐1.02)
0.95 (0.94‐0.96)***
1.16 (1.09‐1.24)***
1.32 (1.24‐1.39)***
0.95 (0.95‐0.96)***
1.29 (1.21‐1.38)***

1.03 (1.01‐1.04)***
0.95 (0.94‐0.96)***
1.09 (1.00‐1.15)
1.12 (1.05‐1.21)***
1.00 (0.98‐1.01)
1.09 (1.01‐1.17)*

73.2 (35.8‐150.0)
40 (30‐54)
3 (1.3‐7.8)
66.8

75 (36.0‐150.0)
36 (27‐47)
5 (2‐12)
67.6

1.00 (1.00‐1.00)***
0.96 (0.95‐0.97)***
1.02 (1.00‐1.04)*
2.05 (1.6‐2.7)***

1.00 (1.00‐1.00)
0.99 (0.98‐1.00)**
1.05 (1.02‐1.07)***
1.04 (0.73‐1.47)

3.2 (2.3)

3.7 (2.5)

1.20 (1.14‐1.27)***

1.09 (1.03‐1.16)**

3.2 (1.1)
11.0 (6.3)
7.0 (5.5)
2 (0‐6)
2 (0‐6)
22
32.6
25.8
18.2

3.1 (1.1)
11.4 (6.3)
6.9 (5.5)
1 (0‐4)
1 (0‐5)
21
30.1
23.4
17.6

0.68 (0.60‐0.77)***
1.16 (1.14‐1.19)***
1.20 (1.16‐1.2)***
1.28 (1.21‐1.36)***
1.11 (1.07‐1.15)***
3.79 (2.55‐5.64)***
4.90 (3.42‐7.01)***
5.16 (3.40‐7.84)***
7.19 (4.14‐12.50)***

0.94 (0.81‐1.09)
1.01 (0.99‐1.03)
1.00 (0.97‐1.03)
0.97 (0.94‐1.00)*
0.97 (0.94‐1.00)
0.94 (0.65‐1.35)
0.89 (0.65‐1.23)
0.88 (0.62‐1.24)
0.96 (0.65‐1.42)

47.4

43.0

2.02 (1.56‐2.60)***

0.84 (0.62‐1.13)

Table 2. Multinomial regression comparing depression before and after pain with those with no history of depression
(N=1379).

Multivariate

Demographics
Age (years)
Male
Income <$400
Completed tertiary education
In a relationship
Change to employment status
Current Pain and Pain History
Pain severity
Pain interference
Pain self‐efficacy
Physical functioning
Age at first pain onset (years)
Pain Duration (years)
Opioid Medication
Opioid dose (OME)
Age at onset of opioid medication
(years)
Duration of opioids (years)
Pharmaceutical opioid difficulties (%
endorsed int/high problems)
Medication side effects
Support
Social Support
Drug and Alcohol use
Any lifetime substance use disorder1

a

Multivariate2b

(RRR 95%CI)

(RRR 95%CI)

0.96 (0.93‐0.98)**
0.39 (0.25‐0.62)***
0.98 (0.63‐1.51)
0.76 (0.49‐1.18)
0.59 (0.38‐0.91)*
0.90 (0.57‐1.43)

1.00 (0.99‐1.03)
0.74 (0.52‐1.05)
1.21 (0.87‐1.69)
0.90 (0.64‐1.26)
0.89 (0.63‐1.26)
1.64 (1.15‐2.36)**

0.93 (0.81‐1.07)
0.94 (0.82‐1.07)
0.97 (0.95‐0.99*
1.11 (0.99‐1.24)
1.05 (1.03‐1.07)***
1.01 (0.99‐1.03)

0.92 (0.83‐1.03)
1.05 (0.94‐1.17)
0.98 (0.97‐1.00)*
1.11 (1.02‐1.21)*
0.97 (0.96‐0.98)***
1.00 (0.99‐1.01)

1.00 (1.00‐1.00)
0.98 (0.96‐1.00)

1.00 (1.00‐1.00)
0.99 (0.97‐1.00)

0.97 (0.94‐1.01)
1.63 (1.01‐2.63)*

1.00 (0.98‐1.02)
1.28 (0.89‐1.86)

0.87 (0.78‐0.96)**

1.00 (0.93‐1.08)

0.92 (0.75‐1.12)

0.84 (0.71‐0.98)*

1.51 (0.92‐2.45)
Notes: Reference group is group A; *=p≤.05, **=p≤.01, ***=p≤.001
2
R =.197, p<.001.
a
comparison of pre‐pain depression with those that had never experienced depression
b
comparison of post‐pain depression with those that had never experienced depression
1. Excluding pharmaceutical opioids
2.Controlling for PTSD, agoraphobia, panic and borderline personality.

1.16 (0.79‐1.71)

Table 3. Demographic characteristics, mental health, pain and opioid medication history of POINT sample with and without depression broken down by onset of opioids
A. No depression (N=519)
Demographics
Age (years) Mdn (IQR)
64 (53‐72)
Male (%)
48.9
Income <$400 (%)
57.6
Completed tertiary education (%)
34.5
Changed employment status (%)
50.3
In a relationship (%)
63.6
Current Pain
Pain duration (years) Mdn (IQR)
10 (4‐20)
Age at onset of pain (years) Mdn (IQR)
35 (23‐50)
Pain severity (BPI) M(SD)
4.8 (1.9)
Pain interference (BPI) M(SD)
4.9 (2.2)
Pain self‐efficacy (PSEQ) M(SD)
34.4 (13.2)
Physical functioning (Washington Group Scale) M(SD)
3.5 (2.0)
Opioid Medication
Opioid dose (OME) Mdn (IQR)
58.6 (25‐102.9)
Age at onset of opioid medication (years) Mdn(IQR)
49 (35.0‐64.0)
Duration of opioids (years) Mdn (IQR)
4 (1.5‐9)
Pharmaceutical opioid difficulties (PODS)(% endorsed
50.5
int/high problems)
Medication side effects M(SD)
2.7 (2.2)
Current Mental Health
Social Support (MOS‐SS) M(SD)
3.5 (1.1)
Depression (PHQ score) M(SD)
6.2 (5.4)
General anxiety (GAD score) M(SD)
3.0 (3.9)
Social anxiety (SIAS‐6) Mdn (IQR)
0 (0‐1)
Social phobia (SPS‐6) Mdn (IQR)
0 (0‐1)
PTSD (PC‐PTSD) (%)
6.6
Agoraphobia (MINI) (%)
8.1
Panic (MINI) (%)
5.6
Borderline personality disorder (CIDI) (%)
2.9
Substance Use
Any lifetime substance use disorder1 (%)
27.2
Notes: 1. Excluding pharmaceutical opioids; *=p≤.05, **=p≤.01, ***=p≤.001.

B. Pre‐opioid depression
(N=426)

C. Post‐opioid depression
(N=416)

C vs A (ref)

C vs B (ref)

57 (46‐66)
34.7
60.1
36.2
65.2
51.9

54 (46‐62)
46.9
57.0
35.8
74.0
56.0

0.95 (0.94‐0.96)***
0.92 (0.71‐1.19)
0.97 (0.75‐1.26)
1.06 (0.81‐1.39)
2.82 (2.13‐3.73)***
0.73 (0.56‐0.95)*

0.99 (0.98‐1.00)*
1.66 (1.26‐2.19)***
0.88 (0.67‐1.16)
0.97 (0.74‐1.31)
1.52 (1.13‐2.05)**
1.18 (0.90‐1.55)

10 (4‐20)
28 (17‐41)
5.1 (1.8)
6.0 (2.2)
26.7 (12.3)
4.6 (2.1)

13 (6‐21.75)
27 (18‐40)
5.3 (1.6)
6.22 (2.1)
26.3 (13.5)
4.5 (2.3)

1.01 (1.00‐1.02)
0.97 (0.96‐0.98)***
1.17 (1.08‐1.25)***
1.31 (1.23‐1.39)***
0.95 (0.94‐0.96)***
1.26 (1.17‐1.35)***

1.01 (1.00‐1.02)
1.00 (0.99‐1.01)
1.07 (0.99‐1.16)
1.06 (0.99‐1.13)
1.00 (0.99‐1.01)
0.99 (0.93‐1.00)

67.00 (30.3‐149.1)
42 (32.0‐55.0)
4 (1.5‐10)
63.9

86.2 (40.0‐177.5)
31.5 (24.8‐42.0)
6 (2‐12.75)
71.9

1.00 (1.00‐1.01)***
0.94 (0.93‐0.95)***
1.03 (1.01‐1.04)**
2.51 (1.85‐3.41)***

1.00 (1.00‐1.00)*
0.95 (0.95‐0.96)***
1.03 (1.01‐1.05)***
1.44 (1.04‐1.99)*

3.3 (2.4)

3.8 (2.6)

1.22 (1.16‐1.29)***

1.10 (1.04‐1.16)***

3.1 (1.1)
11.1 (6.3)
7.1 (5.5)
2 (0‐5)
2 (0‐6)
23.9
32.6
24.6
19.0

3.1 (1.1)
11.6 (6.3)
6.8 (5.5)
1 (0‐4)
1 (0‐5)
18.8
27.9
24.5
16.1

0.67 (0.59‐0.77)***
1.17 (1.14‐1.20)***
1.20 (1.16‐1.23)***
1.27 (1.20‐1.34)***
1.10 (1.06‐1.15)***
3.29 (2.15‐5.04)***
4.39 (3.0‐6.43)***
5.49 (3.55‐8.49)***
6.45 (3.63‐11.48)***

0.97 (0.85‐1.12)
1.01 (0.99‐1.03)
0.99 (0.97‐1.02)
0.96 (0.93‐0.99)*
0.97 (0.94‐1.00)*
0.73 (0.53‐1.02)
0.80 (0.59‐1.07)
0.99 (0.73‐1.36)
0.82 (0.57‐1.17)

44.2

46.0

2.28 (1.73‐3.00)***

1.08 (0.82‐1.41)

Table 4. Multinomial regression comparing depression before and after opioids with those with no history of depression
(N=1361)
Multivariatea

Demographics
0.97 (0.95‐0.99)**
Age (years)
0.46 (0.31‐0.67)***
Male
1.18 (0.83‐1.69)
Income <$400
0.95 (0.67‐1.36)
Completed tertiary education
0.64 (0.45‐0.92)*
In a relationship
1.17 (0.79‐1.72)
Change in employment status
Current Pain
0.92 (0.82‐1.04)
Pain severity
1.00 (0.89‐1.12)
Pain interference
0.98 (0.96‐1.00)*
Pain self‐efficacy
1.14 (1.04‐1.25)**
Physical functioning
0.98 (0.97‐0.99)**
Age at first pain onset (years)
1.00 (0.99‐1.02)
Pain Duration (years)
Opioid Medication
1.00 (1.00‐1.00)
Opioid dose (OME)
1.03 (1.01‐1.05)**
Age at onset of opioid medication (years)
1.00 (0.97‐1.02)
Duration of opioids (years)
1.38 (0.93‐2.05)
Pharmaceutical opioid difficulties (%
endorsed int/high problems)
0.92 (0.85‐1.01)
Medication side effects
Support
0.86 (0.73‐1.02)
Social Support
Drug and Alcohol use
1.43 (0.94‐2.17)
Any lifetime substance use disorder1
Notes: Reference group is group A, *=p≤.05, **=p≤.01, ***=p≤.001
R2=.17, p<.001.
a
b

comparison of pre‐opioid depression with those that had never experienced depression
comparison of post‐opioid depression with those that had never experienced depression

1. Excluding pharmaceutical opioids
2.Controlling for PTSD, agoraphobia, panic and borderline personality.

Multivariate2b
(OR 95%CI)
1.01 (0.99‐1.03)
0.84 (0.57‐1.24)
1.06 (0.73‐1.55)
0.84 (0.58‐1.22)
0.89 (0.61‐1.31)
1.37 (0.91‐2.05)
0.94 (0.83‐1.06)
1.04‐1.17)
0.98 (0.97‐1.00)
1.11 (1.01‐1.22)*
1.01 (0.99‐1.02)
1.00 (0.98‐1.02)
1.00 (1.00‐1.00)
0.94 (0.93‐0.96)***
1.00 (0.98‐1.03)
1.58 (1.04‐2.39)*
1.00 (0.92‐1.09)
0.79 (0.66‐0.95)*
1.04 (0.69‐1.59)

